Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cells

  • Blood Adv. 2026 Jul 14;10(13):4450-4454. doi: 10.1182/bloodadvances.2025018126.
Dominic Pizzarella  1 ,  Amanda Kofides  1 ,  John M Hatcher  1 ,  Xia Liu  1 ,  Alberto Guijosa  1 ,  Nickolas Tsakmaklis  1 ,  Abigail L Peachey  1 ,  Jinhua Wang  2  3 ,  Maria Luisa Guerrera  1 ,  Christopher J Patterson  1 ,  Zachary R Hunter  1 ,  Hao Sun  1 ,  Shayna R Sarosiek  1 ,  Jorge J Castillo  1 ,  Sara J Buhrlage  2  3 ,  Sirano Dhe-Paganon  2  3 ,  Andrew R Branagan  4 ,  Steven P Treon  1 ,  Shirong Liu  1
Affiliations
  • 1. Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • 2. Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA.
  • 3. Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
  • 4. Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
PMID: 41985014 DOI: 10.1182/bloodadvances.2025018126
Products